Vaccine surveillance: monitoring adverse events and safety program evaluation

• SS 11-01 • Epidemiological assessment of HPV safety – distinguishing cause from coincidence See abstract > N. Nick Andrews • SS 11-02 • Monitoring 9-valent human papillomavirus vaccine safety, United States See abstract > L. Lauri MARKOWITZ • SS 11-03 • Ireland: HPV vaccine concerns in Ireland See abstract > B. Brenda CORCORAN • SS 11-04 • The rise and the fall of the Danish HPV vaccination programme, and the way ahead See abstract > K. Kare MØLBAK • SS 11-05 • Japan: Update on HPV vaccine situation in Japan > S. Sharon HANLEY • SS 11-06 • Country responses to vaccine hesitancy and barriers to implementation > J. Jo YARWOOD • SS 11-07 • Monitoring HPV vaccination in the Netherlands: data on vaccine effectiveness and safety up to 7 years post-introduction See abstract > H. Hester DE MELKER